Next Article in Journal
Artificial Intelligence-Based Opportunities in Liver Pathology—A Systematic Review
Previous Article in Journal
Strain Rate Changes during Stress Echocardiography Are the Most Accurate Predictors of Significant Coronary Artery Disease in Patients with Previously Treated Acute Coronary Syndrome
Previous Article in Special Issue
Radiotherapy, Chemotherapy and Immunotherapy—Current Practice and Future Perspectives for Recurrent/Metastatic Oral Cavity Squamous Cell Carcinoma
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Diagnostics
Volume 13
Issue 10
10.3390/diagnostics13101798
diagnostics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Low Prevalence of HSV-1 and Helicobacter pylori in HNSCC and Chronic Tonsillitis Patients Compared to Healthy Individuals

by
Joanna Katarzyna Strzelczyk
1,*,
Agata Świętek
1,2,
Dorota Hudy
1,
Karolina Gołąbek
1,
Jadwiga Gaździcka
1,
Katarzyna Miśkiewicz-Orczyk
3,
Wojciech Ścierski
3,
Janusz Strzelczyk
4 and
Maciej Misiołek
3
1
Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, Poland
2
Silesia LabMed Research and Implementation Center, Medical University of Silesia in Katowice, 19 Jordana St., 41-808 Zabrze, Poland
3
Department of Otorhinolaryngology and Oncological Laryngology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 10 C Skłodowskiej St., 41-800 Zabrze, Poland
4
Department of Endocrinology and Neuroendocrine Tumors, Department of Pathophysiology and Endocrinology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 35 Ceglana St., 40-514 Katowice, Poland
*
Author to whom correspondence should be addressed.
Diagnostics 2023, 13(10), 1798; https://doi.org/10.3390/diagnostics13101798
Submission received: 26 April 2023 / Revised: 12 May 2023 / Accepted: 16 May 2023 / Published: 19 May 2023
(This article belongs to the Special Issue Advances in Diagnostics of Head and Neck Cancer: Volume II)
Browse Figure
Versions Notes

Abstract

:
Recent studies identified viral and bacterial factors, including HSV-1 and H. pylori, as possible factors associated with diseases such as chronic tonsillitis and cancers, including head and neck squamous cell carcinoma (HNSCC). We assessed the prevalence of HSV-1/2 and H. pylori in patients with HNSCC, chronic tonsillitis, and healthy individuals using PCR after DNA isolation. Associations were sought between the presence of HSV-1, H. pylori, and clinicopathological and demographic characteristics and stimulant use. HSV-1 and H. pylori were most frequently identified in controls (HSV-1: 12.5% and H. pylori: 6.3%). There were 7 (7.8%) and 8 (8.6%) patients with positive HSV-1 in HNSCC and chronic tonsillitis patients, respectively, while the prevalence of H. pylori was 0/90 (0%) and 3/93 (3.2%), respectively. More cases of HSV-1 were observed in older individuals in the control group. All positive HSV-1 cases in the HNSCC group were associated with advanced tumor stage (T3/T4). The prevalence of HSV-1 and H. pylori was highest in the controls compared to HNSCC and chronic tonsillitis patients, which indicates that the pathogens were not risk factors. However, since all positive HSV-1 cases in the HNSCC group were observed only in patients with advanced tumor stage, we suggested a possible link between HSV-1 and tumor progression. Further follow-up of the study groups is planned.

1. Introduction

Helicobacter pylori is a Gram-negative, spiral-shaped bacterium that colonizes the gastric and duodenal mucosa. By developing special mechanisms such as motility and urease secretion, it can survive in unfavorable living conditions [1]. There are two routes of infection, i.e., oral-oral and oral-fecal. The main risk factors include poor housing, economic conditions, and genetic and racial predisposition. H. pylori infection has been recognized as an infectious disease regardless of the onset of symptoms. While most infected individuals remain asymptomatic, H. pylori has been proven to be associated with such infections. It usually causes chronic bacterial infection and is mainly related to gastritis, peptic ulcers, gastrointestinal disorders, and gastric cancer [2].
Most individuals with H. pylori infection are diagnosed in developing countries (80–95%) [3], while in European countries, the infection rate is 20–40% [4]. Of note, about 4.4 billion people worldwide were infected in 2015 [5]. According to the epidemiological data from a multicenter study conducted in Poland in 2002 and 2003, H. pylori infection affected 84% of adults [6]. In the diagnosis of H. pylori infection, invasive methods are used. They involve the analysis of gastric mucosal samples taken during endoscopy and non-invasive methods (serological tests detecting specific IgG class antibodies, the C13 urea breath test, and the stool antigen test) [7]. Diverse PCR methods targeting specific H. pylori genes are also known. Detection by PCR is possible using various types of biological material [8].
Herpes simplex virus 1 (HSV-1) is a double-stranded DNA virus transmitted by saliva and through direct contact with mucous membranes and skin. It is usually associated with herpes (cold sores) of the lips and mouth [9]. Additionally, the virus can cause other less common diseases, such as keratitis and encephalitis, especially in immunocompromised individuals [10]. HSV-1 remains permanently in the body in a dormant state in ganglion cells and can be periodically reactivated [11]. Herpes virus infections are widespread among humans. Serologic studies indicate that most adults (up to 95%) are infected [12,13]. Moreover, this infection may be asymptomatic, contributing to the high prevalence of HSV-1 infections worldwide [14].
The most common malignancy involving the head and neck region is squamous cell carcinoma (HNSCC), which develops from epithelial cells of the mucosa of the mouth, pharynx, and larynx [15]. The risk factors for the development of typical HNSCC are well defined and mainly include exposure to tobacco and high-proof alcohol. HNSCC ranks 12th among all types of cancers [16,17]. The etiology of HNSCC consists of many factors, including different infections [9,16]. Several studies have shown positive associations of various pathogens (HSV-1) with oral cancer and precancerous conditions [9,18]. As regards H. pylori, the link between oral cancer and infection is still not determined, as reported by Kuo et al., 2022 [19]. Research in recent years has demonstrated the role of human papillomavirus (HPV) infection, which has the ability to infect human epithelial cells and is the etiologic agent of many types of cancer, including HNSCC. The prevalence varies due to cultural differences, medical practice, and diagnostic procedures [20,21].
Tonsils are part of Waldeyer’s ring, the first line of defense of the mucosa against invading pathogens. One of the most common indications for tonsillectomy is chronic tonsillitis, usually characterized by a sore throat that lasts longer than three months and is accompanied by tonsillar inflammation. Similarly, in the pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections (PANDAS), chronic streptococcal infection increases not only the risk of chronic tonsillitis but also obsessive-compulsive disorders, mainly in children [22]. The relationship between H. pylori infection and the pathogenesis of chronic tonsillitis remains controversial. Some researchers showed that the tonsil tissue could be a reservoir of H. pylori [23,24]. They also found it responsible for gastric reinfection, while other authors did not observe such an association [25,26,27]. To date, there have been limited data on HSV-1 infections in chronic tonsillitis samples [28].
The etiology of HNSCC and chronic tonsillitis is complex and involves many factors, including the presence of pathogens [9,16]. Both HSV and H. pylori are common human pathogens. There is a growing level of interest in their potential role in the initiation and progression of cancer [1,4,9,14]. HSV and H. pylori infections are distributed worldwide with variations in prevalence. Thorough knowledge of bacterial or viral infections is needed to understand their impact on the etiology of the diseases fully. We examined the prevalence of these pathogens to investigate the potential role of HSV and H. pylori in HNSCC and chronic tonsillitis and to provide further data about the epidemiology of HSV and H. pylori infections in adolescents in Poland.
The aim of this study was to determine the prevalence of HSV-1/2 and H. pylori in three groups, i.e., in patients with HNSCC, chronic tonsillitis, and healthy individuals. The aim was also to define the relationship between the presence of the pathogens and clinicopathological and demographic data and the use of stimulants in the study population.

2. Materials and Methods

The present study included 295 volunteers that were Caucasians and lived in Poland. The specimens were collected from healthy individuals (n = 112) and patients diagnosed with HNSCC (n = 90) and chronic tonsillitis (n = 93). Cancer tissue samples were collected postoperatively. The diagnosis of HNSCC was confirmed histologically. Tonsillar tissues were collected after tonsillectomy from patients diagnosed with chronic tonsillitis and were verified by a histopathologist. The samples were collected at the Department of Otorhinolaryngology and Oncological Laryngology in Zabrze, Medical University of Silesia in Katowice.
This retrospective study was carried out with surgical interventions from May 2018 to May 2022. Swab samples from the oral, buccal mucosa were taken from healthy subjects during the same period using cotton swabs. Immediately after collection, the samples from all participants were labeled and stored at −80 °C until further analysis. The exclusion criteria for all groups were age below 18 years and no written informed consent to participate in the study, while in the case of HNSCC, an undiagnosed primary tumor or preoperative radio- and/or chemotherapy, local or nodal recurrence, and the second primary tumor of HNSCC. As regards control and chronic tonsillitis groups, any diagnosed cancer, history of cancer treatment (radiotherapy, chemotherapy), and confirmed or clinically suspected immunodeficiency were the exclusion criteria. Additionally, the presence of any chronic diseases was also an excluding factor in the control group.
The study was conducted in compliance with the Declaration of Helsinki and approved by the Institutional Review Board (IRB No. KNW/0022/KB1/49/16 and No. KNW/0022/KB1/49/II/16/17). All patients and volunteers provided written informed consent before participating in the study.

2.1. Patient Characteristics

Patient demographic data, including age, gender, and baseline data, such as smoking and/or alcohol consumption, were obtained using a self-administered questionnaire. The data are given in Table 1. HNSCC samples were characterized according to the TNM classification in line with the criteria of the American Joint Committee on Cancer (AJCC) 8th edition and the International Union Against Cancer (UICC) [29]. Clinical data of the HNSCC group, including T classification (T), lymph node status (N), and histological grade (G), are summarized in Table 2. The groups were matched in terms of the number of participants and sociodemographic characteristics, except age which was higher in the HNSCC group.

2.2. Methods

2.2.1. DNA Preparation

Prior to the DNA isolation, tumor and tonsil tissue samples were homogenized in FastPrep®-24 (MP Biomedicals, Irvin, CA, USA) with ceramic beads (Lysing Matrix A, MP Biomedicals, Irvin, CA, USA). DNA was isolated from the samples using the Gene Matrix Tissue DNA Purification Kit (Eurx, Gdańsk, Poland). Oral mucosal epithelial cells of the control group were extracted using the GeneMATRIX Swab-Extract DNA Purification Kit (Eurx, Gdańsk, Poland). Spectrophotometry was used to qualitatively and quantitatively evaluate the isolated DNA material (NanoPhotometer Pearl, Implen, Munich, Germany).

2.2.2. Detection of HSV-1/2 and H. pylori

The real-time PCR method was used to detect the presence of the genetic material of the pathogens in the samples. The presence of HSV-1/2 and H. pylori in the specimens from HNSCC, chronic tonsillitis patients, and healthy controls was determined using the commercially available HSV-1/2 PCR kit (HSV/ISEX/100, GeneProof, Brno, Czech Republic) and the AmpliSens Helicobacter pylori-FRT PCR kit (R-B9 (RG,iQ)-CE, Ecoli Dx, s.r.o., Prague, Czech Republic). The tests were performed according to the manufacturer’s instructions using 10 µL of isolated DNA. PCRs were performed using the QuantStudio 5 instrument (Thermo Fisher Scientific, Waltham, MA, USA). Negative, positive, and amplification controls were performed in each test. The positive control was the DNA of H. pylori or HSV-1/2. DNA buffer was used as a negative control in both tests. Positive control STI-88 from the H. pylori kit was the control of amplification for the H. pylori test. The internal standard served as an amplification control for the HSV-1/2 test. The positive criteria for pathogen detection were the correct results for all controls and the CT value for the pathogen ≤ the boundary value specified in the kit. The sensitivity of the H. pylori kit was 1 × 103 H. pylori genome equivalents per ml, and the diagnostic sensitivity of the HSV-1/2 kit was described as 100% (CI95%: 97.08–100%).

2.2.3. Statistical Analysis

Fisher’s exact test was used to determine the differences between the groups. Age differences were checked using Shapiro—Wilk and Mann—Whitney U tests. The level of significant differences was set at p < 0.05. The data were presented as quantity or the median with the range. All statistical analyses were performed using STATISTICA 13.3 (StatSoft. Inc., Tulsa, OK, USA).

3. Results

There was a difference in age between the HNSSC group and the control or chronic tonsillitis group (control vs. chronic tonsillitis p > 0.05; control vs. HNSCC p = 0.007; chronic tonsillitis vs. HNSCC p < 0.001).

The Prevalence of HSV-1/2 and H. pylori in All Study Groups

HSV-1 and H. pylori were most frequently identified in controls (HSV-1: 12.5% and H. pylori: 6.3%). There were seven (7.8%) and eight (8.6%) subjects with positive HSV-1 among HNSCC and chronic tonsillitis patients, respectively (Figure 1A). Positive HSV-2 was not found in the study groups. The prevalence of H. pylori in patients with HNSCC and those with chronic tonsillitis was 0% and 3.2%, respectively (Figure 1B). There were statistical differences in the prevalence of H. pylori between the control and HNSCC groups (p = 0.035). No other differences were found between the groups regarding the prevalence of HSV-1 or H. pylori (p > 0.05), as shown in Table 3.
There were no differences between the prevalence of HSV-1 and H. pylori and age, gender, drinking and/or smoking status (p > 0.05) in all groups except for the control group and the presence of HSV-1. In the control group, there were more positive cases of HSV-1 in older individuals (≥40 years of age) (p = 0.042, Table 4).
All positive HSV-1 cases in the HNSCC group were associated with advanced tumor stage (T3/T4, p = 0.048, Table 5). Six of seven cases in the HNSCC group were patients with T4 classification (p = 0.005, Table 5). All cases of HSV-1 were observed in stage IV, which was significant (p = 0.044, Table 5). There were no associations between histological grade and nodal status and the occurrence of HSV-1 (Table S1). Additionally, no difference was found in all groups between the prevalence of HSV-1 and H. pylori and smoking and regular or occasional drinking (p > 0.05, Table S2).

4. Discussion

HSV-1 has been identified as a risk factor for the development of some human malignancies, particularly in association with stimulants such as tobacco and alcohol. Several studies have confirmed a possible correlation between herpes virus infection and head and neck cancers [11,30,31]. HSV-1 has the potential to block programmed cell death and can produce factors that can induce apoptosis in immune cells, such as T cells, B cells, macrophages, and dendritic cells [32,33]. Studies suggested that the presence of HSV-1 was associated with impaired DNA damage repair and amplification of pre-existing oncogenes in tumor tissues [34,35]. Other studies confirmed that HSV-1 could affect the inhibition of apoptosis of infected cells via ICP-0, Us3, and Us5 proteins. It affects the impaired regulation of cellular apoptotic pathways such as p53. As a result, cell death does not occur until HSV-1 infection develops at a high viral copy number [36,37,38]. Interestingly, several studies have demonstrated that HSV-1 has the ability to reactivate in critically ill patients with COVID-19 [39]. In studies on different materials obtained from patients (bronchoalveolar lavage fluid [BALF], tracheal aspirate, and blood), HSV-1 was confirmed in an average of 40% of samples. This supports the theory that some viruses can cause reactivation of other viruses. It was speculated that systemic or pulmonary reactivation of HSV-1 could be related to immune system impairment caused by SARS-CoV-2 [39].
The literature data show the prevalence of HSV in HNSCC ranges from 5% to 25% [40,41]. Moreover, the infection was mostly asymptomatic in patients with HNSCC [42]. A Polish study using PCR showed the presence of the HSV-1 genome in 7.5% of tumor tissue samples from 80 patients with oral squamous cell carcinoma (OSCC), which is also in line with our study (7.8%; 8/90). The authors emphasized the need for further studies on a larger cohort to determine the potential role of HSV-1 as an infection cofactor in HNSCC [43]. Similarly, a study on the Sudanese population reported the prevalence of HSV-1 at 7.5% in OSCC tissue samples [44]. Low rates of HSV-1 infection (1.92–4.8%) were reported in other studies [41,45]. As in our study, several previous reports also failed to confirm a significant association between HSV-1 and the risk of HNSCC [31,46,47]. A population-based study by Starr et al. [11] reported that the presence of HSV-1 was associated with a slightly increased risk of OSCC [11]. Another study suggested that HSV-1 could play an important role in OSCC, as they showed statistical significance in the mandibular location (18.6% positive cases) [48]. In a case report of a patient with HSV-1-positive laryngeal squamous cell carcinoma (LSCC), changes were observed in cell nuclei and cytoplasmic tails between cells, which may indicate a potential link between the herpes virus and the occurrence of LSCC [49]. The question arises as to whether the herpes virus can initiate cancer or whether HSV-1 infection can be superimposed due to an immunocompromised state in cancer patients. Interestingly, higher levels of IgM antibodies to HSV-1 were observed in the serum of oral cancer patients compared to control subjects of the same age [50]. Similarly, another study found that IgG levels were elevated in cancer patients compared to healthy individuals [9]. It was hypothesized that the elevated level of antibodies to HSV-1 in patients with OSCC could be related to the oncogenic potential of HSV [51]. Current treatments involving pharmacotherapy, chemotherapy, radiation therapy, or surgery can cause many adverse effects. Accordingly, the use of immunotherapy with oncolytic viruses has recently become the subject of extensive research. Native or genetically recombinant viruses have the ability to selectively infect cancer cells and cause their disintegration without affecting normal cells. Because of its wide host range and large genome, HSV-1 is used in the destruction of cancer cells. After entering the host cell, HSV-1 replicates in the nucleus and can induce programmed cell death, pyroptosis, necrosis, and autophagy [52]. Further research focusing on efficacy, safety, and high cytotoxicity is warranted.
The prevalence of HSV-1 was highest in the control group, which indicates that HSV-1 was not a risk factor in our HNSCC group, although all positive HSV-1 cases were found only in patients with advanced tumor stage (T3/T4). It suggests that HSV-1 can modulate cancer progression. The effects of specific molecular mechanisms of HSV-1 on tumors are not fully explained, but some studies showed contribution to tumor progression. The search of medical databases (Pubmed, Medline) did not show other reports indicating the associations between HSV-1 and tumor stage in HNSCC patients. However, a study on brain glioma reported the presence of HSV-1 only at a higher tumor stage (WHO lV), which aligns with our findings [53]. The presence of the virus was absent at lower stages. In a study of central nervous system tumors, a hypothesis was proposed that HSV-1/2 could be involved in modulating the retinoblastoma suppressor pathway and, therefore, could play a role in oncogenesis [54]. In addition, it was suggested that HSV-1/2 could affect various intracellular signaling pathways, which implies oncogenic changes in cells and could also exacerbate the already existing cancerous changes [55]. Another study reported the importance of viral miRNA, which can interfere with the expression of infected miRNA, thereby affecting the formation and development of tumors. Additionally, there is a theory that HSV 1/2 may facilitate tumor progression through miRNA modulation of tumors [56].
To the best of our knowledge, there are only a few single studies describing HSV detection in tonsillar tissue samples [57,58,59]. HSV was not detected by in situ hybridization (ISH) in any tonsil samples [57]. Using PCR, another study showed 7.4% positive tonsils samples for HSV-1 and none for HSV-2 [58]. Another research assessed tissue samples taken from the core of the tonsils in children and adults with recurrent tonsillitis and tonsillar hypertrophy, and 1.8% (1/56) was positive for HSV [59]. In our study, we detected HSV-1 in 8.6% of patients with chronic tonsillitis (8/93). No significant differences were found between patients with chronic tonsillitis and controls. Therefore, our results confirm the previous findings of other researchers. It appears that HSV infection is not a factor associated with tonsillitis. Of note, recurrent inflammatory infections, particularly viral, have an impact on tonsillar hypertrophy and increase the risk of obstructive sleep apnea (OSA) [60,61]. Continuous positive airway pressure (cPAP) is the most common treatment of sleep apnea syndrome, especially in moderate and severe diseases [62,63,64]. Additionally, nasal surgery, pharyngeal surgery, and/or maxillomandibular surgery are effective methods of OSA treatment [65,66,67].
A study analyzing 182 papers reported that the global prevalence of oral HSV-1 was 63.6% in 2016 and was highest in the South-East Asia Region. Detection of HSV was performed using type-specific immunoglobulin G antibodies. Furthermore, the infection of oral HSV-1 was associated with age [68]. Another meta-analysis showed that the seroprevalence of HSV-1 in the healthy adult European population was 73.6% and increased with age. The highest seroprevalence was found in Eastern Europe (87.9%), while the lowest (57.7%) was observed in Northern Europe [69]. The estimates of the prevalence of HSV-2 in 2016 showed that 13.2% of individuals aged 15–49 years had immunoglobulin G antibodies for HSV-2, and the highest prevalence was observed in Africa and increased with age and gender [68]. In our study, we reported that 12.5% of controls were HSV-1 positive, while none of the controls was HSV-2 positive. In another Polish study, the level of anti-HSV IgG antibodies in controls was 6% [70]. The prevalence of HSV infection varies greatly depending on the continent, country, population, or HSV type. It was found that the detection of HSV-1 was significantly higher than HSV-2 (87–35% for HSV-1 compared to 17–8% for HSV-2) [71,72,73,74,75,76,77,78,79]. Furthermore, in our study, the presence of the HSV-1 virus was associated with higher age. Similar results were shown in other studies where the prevalence of HSV-1 infection increased with the age of patients [73,74]. Our results could confirm previous observations on the relationship between viral infection and the age of patients. A higher prevalence of the virus in older patients could be associated with immunosenescence [80].
Of note, the obtained results may be related to research methods. The serological tests may confirm the prevalence of HSV-1 and HSV-2. However, they did not indicate the site of infection, such as the mouth or genital area [81]. Moreover, oral HSV shedding had an influence on the positive results of PCR detection [14,82]. Some studies analyzed oral HSV shedding using PCR from swab samples collected daily from HSV-seropositive patients. The presence of HSV in oral mucosa was confirmed by PCR only on 3.7–26% of overall days [14,83,84,85]. Because viral shedding is episodic, increasing the sampling frequency on overall days increased the detection rate of the virus by PCR [85]. Moreover, the rate of HSV detection was various and was not associated with lesions or prodrome [14].
In our study, we did not show the presence of HSV-2. Similarly, some studies found no oral HSV-2 in controls [82,86]. It may be associated with the differences at the site of reactivation between HSV-1 and HSV-2. HSV-1 is mostly reactivated from trigeminal ganglia compared to HSV-2, which is reactivated from lumbosacral ganglia [87]. Moreover, the possibility of detecting oral asymptomatic HSV-1 infection was 7.5 times higher than oral HSV-2 infection [82].
As in gastric cancer, it was speculated that H. pylori could be involved in modifying the host immune response, which contributes to the progression of oral and oropharyngeal cancer, as confirmed by several studies [16,88,89]. Both indirect (inflammation) and direct (induction of protein modulation and genetic mutations) effects of H. pylori on gastric epithelial cell function were demonstrated. However, other tissues may also be affected [90]. Many studies confirmed the presence of H. pylori in the middle ear, oral cavity, larynx, saliva, nasal and sinus mucosa, and pharyngeal lymphoid tissue [91,92,93,94,95]. The study results suggest that these locations were not only potential reservoirs for microbial infection and gastric reinfection but also provided preliminary information on the correlation of H. pylori infection with the development of HNSCC [96].
In our study, we did not confirm the presence of H. pylori in HNSCC patients (0/90 samples). Previous studies have reported that the prevalence of H. pylori in HNSCC ranged from 0–40%. Based on the meta-analysis of 11 studies, it was concluded that PCR was the best technique for detecting H. pylori in laryngeal or pharyngeal tissue, which was also used in our study due to its high specificity and sensitivity of almost 100% [97]. The significantly higher percentage of positive results for H. pylori was described in cases of laryngeal and pharyngeal cancer [16,96,98,99,100]. Several recent studies using quantitative polymerase chain reaction (qPCR) and IHC have not confirmed the presence of H. pylori in patients with LSCC or HNSCC [88,101,102,103,104,105]. In a Polish study by Burduk [106] on laryngeal squamous cell carcinoma (LSCC) samples using the urease test, a high percentage of H. pylori was confirmed (62.5%; 50/80) [106]. Another study by Burduk [107] showed that the H. pylori cagA gene was observed in 46.7% and 49.3% of laryngeal cancer samples, depending on tissue location. In addition, an association was found between the presence of cagA and clinical stage T3 and T4, which may indicate H. pylori as a potential carcinogen [107]. Other studies based on the same material also showed positive results for more than 75% of samples [98,108,109,110,111]. It could be explained by the association of H. pylori infection with the occurrence of laryngopharyngeal or gastric reflux and the colonization of the laryngeal region and the pharynx [112]. As a result, epithelial cells are damaged, and the subsequent inflammatory process can lead to chronic damage and the subsequent development and progression of cancer [113].
Some studies suggest the association between H. pylori and upper respiratory tract diseases, such as tonsillitis, rhinitis, and rhinosinusitis [114,115]. H. pylori is likely to colonize the tonsillar surface and core tissues [116]. In our study, we detected H. pylori only in 3.2% of patients with chronic tonsillitis. The role of H. pylori in the pathogenesis of chronic tonsillitis is still unclear. The meta-analysis based on six studies [26,98,117,118,119,120], including 462 patients from different populations, showed that H. pylori had a significant effect on chronic tonsillitis compared with non-infectious indications for tonsillectomy (e.g., obstruction, hypertrophy). Additionally, H. pylori played a role in chronic tonsillitis in children but not in adults [121]. The method of detecting the pathogen also influenced the results [121]. It should be noted that the rapid urease test could lead to higher rates of false-positive results because other urease-producing species (except H. pylori) are present in the oral cavity as opposed to the stomach tissue [122].
In our study, the rate of H. pylori infection in healthy individuals was 6.3%, the highest in all study groups. Other studies based on the adult healthy Polish population showed the infection rate ranging from 39% to 84.19% [6,123,124]. Studies showed that the prevalence of H. pylori in healthy populations was different depending on the country. In the European population, the rate of infection was very wide. In the Czech Republic, 12% to 23.5% [111,125], while higher rates were reported in Hungary (32%) and the Netherlands (30%) [126,127]. Spain was the country with the highest prevalence of H. pylori (87.2%) [128]. According to one review, the prevalence of H. pylori was lower in Northern and Western Europe, while the highest infection rate was observed in Southern and Eastern Europe [129]. In Asia, it ranged from 18% to 35% in the Chinese population [121,130], 40% in Japan [131], 41% in the United Arab Emirates [3], and 62% in Kazakhstan [132]. Additionally, the infection rate was 65% in Brazil [133], while the prevalence of H. pylori was 13% in Canada [134].
In our study, we found no association between the presence of H. pylori and the selected parameters, such as age, gender, smoking, and drinking. Some studies found that the risk of infection was strongly associated with age [3,125,127,128,130,133], while other studies did not find such a relationship [130,134]. Moreover, the association between infection and gender was reported by Lorenzo et al. [128] (men had a higher risk of infection) [128]. However, other studies did not confirm it [125,132,133]. In addition, it was reported that the risk of H. pylori infection was associated with increased salt intake [132], sharing a bedroom with three or more persons [3,133], cigarette smoking, consumption of high-proof alcohol or not washing hands after coming back home [6], higher BMI [128], lower education level [133] or rural place of birth [6,127,130].
The differences in the results may be connected with a different detection method: the C-urea breath test, [125,130,131], IHC [121], the stool antigen test [3], the serological test [126,127,128] and real-time PCR [111]. In addition, the detection of H. pylori from the samples obtained from the oral cavity by different PCR methods may be difficult due to the presence of other 700 bacterial species and requires appropriate and specific primers [135,136]. Furthermore, ethnicity may influence susceptibility to H. pylori infection [133,134]. Willems et al. (2020) observed differences between the ethnic groups in Canada. Caucasians had the lowest infection rate (8%), while African, Asian, and South American populations had infection rates of 25%, 30%, and 34%, respectively, which suggested that race could be associated with susceptibility to infection [134].

Limitations of the Study

The main limitation of the study is the difference in age between the HNSCC group and control/chronic tonsillitis groups, as shown in the Section 3. This study is also limited by a small number of samples. Therefore, to confirm the associations more accurately, future studies should be conducted on larger cohorts. Furthermore, considering viral and bacterial infections is needed to understand their impact on cancer progression fully. In the future, our studies will focus on the analysis of disease-free and overall survival in HNSCC patients.

5. Conclusions

To conclude, the prevalence of HSV-1 and H. pylori was highest in the control group compared to HNSCC and chronic tonsillitis, which indicates that the pathogens are not risk factors in the study groups. However, since all positive HSV-1 cases in the HNSCC group were found only in patients with advanced tumor stage, we suggest a possible link between HSV-1 and tumor progression. The knowledge of epidemiology is of great importance to public health. Given the prevalence of HSV-1 and H. pylori and the risk of severe disease, attention should be paid to screening, diagnosis, and prevention of infection, including the need to develop widely available rapid methods for effective detection. We plan to monitor the health status of our study groups and perform a long-term follow-up of their condition.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/diagnostics13101798/s1, Table S1 The prevalence of HSV-1 and H. pylori in the HNSCC group according to nodal status and histological, Table S2 The prevalence of HSV-1 or H. pylori and the sociodemographic characteristics (age, gender, drinking, and smoking status) in patients with HNSCC, chronic tonsillitis, and controls. grade.

Author Contributions

Conceptualization, J.K.S.; methodology, J.K.S., A.Ś. and D.H.; formal analysis, J.K.S.; investigation, J.K.S. and D.H.; data curation, J.K.S., D.H., J.G., K.G., K.M.-O., W.Ś. and M.M.; writing—original draft preparation, J.K.S., A.Ś., D.H., J.G. and K.G.; writing—review and editing, K.M.-O., W.Ś., J.S. and M.M.; visualization, D.H. and J.S.; supervision, J.K.S.; project administration, J.K.S.; funding acquisition, J.K.S. All authors have read and agreed to the published version of the manuscript.

Funding

This work was supported by funding from the Ministry of Science and Higher Education: PCN-1-187/N/0/O.

Institutional Review Board Statement

The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board on Medical Ethics, No. KNW/0022/KB1/49/16 and No. KNW/0022/KB1/49/II/16/17.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data used to support the findings of this research are available upon request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Ansari, S.; Yamaoka, Y. Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity. Toxins 2019, 11, 677. [Google Scholar] [CrossRef] [PubMed]
  2. Bai, X.; Zhu, M.; He, Y.; Wang, T.; Tian, D.; Shu, J. The impacts of probiotics in eradication therapy of Helicobacter pylori. Arch. Microbiol. 2022, 204, 692. [Google Scholar] [CrossRef] [PubMed]
  3. Khoder, G.; Muhammad, J.S.; Mahmoud, I.; Soliman, S.S.M.; Burucoa, C. Prevalence of Helicobacter pylori and Its Associated Factors among Healthy Asymptomatic Residents in the United Arab Emirates. Pathogens 2019, 8, 44. [Google Scholar] [CrossRef] [PubMed]
  4. Venneman, K.; Huybrechts, I.; Gunter, M.J.; Vandendaele, L.; Herrero, R.; Van Herck, K. The epidemiology of Helicobacter pylori infection in Europe and the impact of lifestyle on its natural evolution toward stomach cancer after infection: A systematic review. Helicobacter 2018, 23, e12483. [Google Scholar] [CrossRef]
  5. Hooi, J.K.Y.; Lai, W.Y.; Ng, W.K.; Suen, M.M.Y.; Underwood, F.E.; Tanyingoh, D.; Malfertheiner, P.; Graham, D.Y.; Wong, V.W.S.; Wu, J.C.Y.; et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology 2017, 153, 420–429. [Google Scholar] [CrossRef]
  6. Łaszewicz, W.; Iwanczak, F.; Iwanczak, B. Seroprevalence of Helicobacter pylori infection in Polish children and adults depending on socioeconomic status and living conditions. Adv. Med. Sci. 2014, 59, 147–150. [Google Scholar] [CrossRef]
  7. Repici, A.; Pellicano, R.; Astegiano, M.; Saracco, G.; De Angelis, C.; Debernardi, W.; Berrutti, M.; Rizzetto, M. La diagnosi “invasiva” dell’infezione da Helicobacter pylori nella pratica clinica del 2006 [Invasive diagnosis of Helicobacter pylori infection in the 2006 clinical practice]. Minerva Med. 2006, 97, 25–29. [Google Scholar]
  8. Rimbara, E.; Sasatsu, M.; Graham, D.Y. PCR detection of Helicobacter pylori in clinical samples. Methods Mol. Biol. 2013, 943, 279–287. [Google Scholar]
  9. Jain, M. Assesment of Correlation of Herpes Simplex Virus-1 with Oral Cancer and Precancer-A Comparative Study. J. Clin. Diagn. Res. 2016, 10, ZC14–ZC17. [Google Scholar] [CrossRef]
  10. Packard, J.E.; Dembowski, J.A. HSV-1 DNA Replication—Coordinated Regulation by Viral and Cellular Factors. Viruses 2021, 13, 2015. [Google Scholar] [CrossRef]
  11. Starr, J.R.; Daling, J.R.; Fitzgibbons, E.D.; Madeleine, M.M.; Ashley, R.; Galloway, D.A.; Schwartz, S.M. Serologic evidence of herpes simplex virus 1 infection and oropharyngeal cancer risk. Cancer Res. 2001, 61, 8459–8464. [Google Scholar] [PubMed]
  12. Looker, K.J.; Magaret, A.S.; May, M.T.; Turner, K.M.; Vickerman, P.; Gottlieb, S.L.; Newman, L.M. Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012. PLoS ONE 2015, 10, e0140765. [Google Scholar] [CrossRef] [PubMed]
  13. Arshad, Z.; Alturkistani, A.; Brindley, D.; Lam, C.; Foley, K.; Meinert, E. Tools for the Diagnosis of Herpes Simplex Virus 1/2: Systematic Review of Studies Published Between 2012 and 2018. JMIR Public Health Surveill. 2019, 5, e14216. [Google Scholar] [CrossRef]
  14. Ramchandani, M.; Kong, M.; Tronstein, E.; Selke, S.; Mikhaylova, A.; Magaret, A.; Huang, M.L.; Johnston, C.; Corey, L.; Wald, A. Herpes Simplex Virus Type 1 Shedding in Tears and Nasal and Oral Mucosa of Healthy Adults. Sex. Transm. Dis. 2016, 43, 756–760. [Google Scholar] [CrossRef] [PubMed]
  15. Johnson, D.E.; Burtness, B.; Leemans, C.R.; Lui, V.; Bauman, J.E.; Grandis, J.R. Head and neck squamous cell carcinoma. Nat. Rev. Dis. Prim. 2020, 6, 92. [Google Scholar] [CrossRef]
  16. Dayama, A.; Srivastava, V.; Shukla, M.; Singh, R.; Pandey, M. Helicobacter pylori and oral cancer: Possible association in a preliminary case control study. Asian Pac. J. Cancer Prev. 2011, 12, 1333–1336. [Google Scholar]
  17. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef]
  18. Jalouli, J.; Ibrahim, S.O.; Mehrotra, R.; Jalouli, M.M.; Sapkota, D.; Larsson, P.A.; Hirsch, J.M. Prevalence of viral (HPV, EBV, HSV) infections in oral submucous fibrosis and oral cancer from India. Acta Oto-Laryngol. 2010, 130, 1306–1311. [Google Scholar] [CrossRef]
  19. Kuo, Y.C.; Yu, L.Y.; Wang, H.Y.; Chen, M.J.; Wu, M.S.; Liu, C.J.; Lin, Y.C.; Shih, S.C.; Hu, K.C. Effects of Helicobacter pylori infection in gastrointestinal tract malignant diseases: From the oral cavity to rectum. World J. Gastrointest. Oncol. 2022, 14, 55–74. [Google Scholar] [CrossRef]
  20. Smith, E.M.; Ritchie, J.M.; Summersgill, K.F.; Hoffman, H.T.; Wang, D.H.; Haugen, T.H.; Turek, L.P. Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J. Natl. Cancer Inst. 2004, 96, 449–455. [Google Scholar] [CrossRef]
  21. Golusiński, W.; Leemans, C.R.; Dietz, A. HPV Infection in Head and Neck Cancer, 1st ed.; Springer: Cham, Switzerland, 2017; pp. 4–18, 58, 73–78, 113–123. [Google Scholar]
  22. Cocuzza, S.; Marino, S.; Gulino, A.; Pustorino, E.; Murabito, P.; Maniaci, A.; Sabino, L.; Taibi, R.; Di Luca, M.; Falsaperla, R.; et al. ENT involvement and orobuccal movements’ disorders in Pandas patients: Assessment and rehabilitations tools. Eur. Rev. Med. Pharmacol. Sci. 2019, 23, 4110–4117. [Google Scholar] [PubMed]
  23. Pytko-Polonczyk, J.; Konturek, S.J.; Karczewska, E.; Bielański, W.; Kaczmarczyk-Stachowska, A. Oral cavity as permanent reservoir of Helicobacter pylori and potential source of reinfection. J. Physiol. Pharmacol. 1996, 47, 121–129. [Google Scholar] [PubMed]
  24. Kim, N.; Lim, S.H.; Lee, K.H.; You, J.Y.; Kim, J.M.; Lee, N.R.; Jung, H.C.; Song, I.S.; Kim, C.Y. Helicobacter pylori in dental plaque and saliva. Korean J. Intern. Med. 2000, 15, 187–194. [Google Scholar] [CrossRef] [PubMed]
  25. Bulut, Y.; Agacayak, A.; Karlidag, T.; Toraman, Z.A.; Yilmaz, M. Association of cagA+ Helicobacter pylori with adenotonsillar hypertrophy. Tohoku J. Exp. Med. 2006, 209, 229–233. [Google Scholar] [CrossRef] [PubMed]
  26. Jelavic, B.; Bevanda, M.; Ostojic, M.; Leventic, M.; Vasilj, M.; Knezevic, E. Tonsillar colonization is unlikely to play important role in Helicobacter pylori infection in children. Int. J. Pediatr. Otorhinolaryngol. 2007, 71, 585–590. [Google Scholar] [CrossRef]
  27. Toros, S.Z.; Toros, A.B.; Kaya, K.S.; Deveci, I.; Özel, L.; Naiboğlu, B.; Habeşoğlu, T.; Egeli, E. A study to detect Helicobacter pylori in adenotonsillar tissue. Ear Nose Throat J. 2011, 90, E32. [Google Scholar] [CrossRef]
  28. Kourieh, A.; Gheit, T.; Tommasino, M.; Dalstein, V.; Clifford, G.M.; Lacau St Guily, J.; Clavel, C.; Franceschi, S.; Combes, J.D. SPLIT study group. Prevalence of human herpesviruses infections in nonmalignant tonsils: The SPLIT study. J. Med. Virol. 2019, 91, 687–697. [Google Scholar] [CrossRef]
  29. Lydiatt, W.M.; Patel, S.G.; O’Sullivan, B.; Brandwein, M.S.; Ridge, J.A.; Migliacci, J.C.; Loomis, A.M.; Shah, J.P. Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J. Clin. 2017, 67, 122–137. [Google Scholar] [CrossRef]
  30. Ahmed, S.; Jafarey, N.A. Association of herpes simplex virus type-I and human papilloma virus with carcinoma of the oral cavity and oropharynx. J. Environ. Pathol. Toxicol. Oncol. 1995, 14, 193–196. [Google Scholar]
  31. Parker, T.M.; Smith, E.M.; Ritchie, J.M.; Haugen, T.H.; Vonka, V.; Turek, L.P.; Hamsikova, E. Head and neck cancer associated with herpes simplex virus 1 and 2 and other risk factors. Oral Oncol. 2006, 42, 288–296. [Google Scholar] [CrossRef]
  32. Hanon, E.; Hoornaert, S.; Dequiedt, F.; Vanderplasschen, A.; Lyaku, J.; Willems, L.; Pastoret, P.P. Bovine herpesvirus 1-induced apoptosis occurs at the G0/G1 phase of the cell cycle. Virology 1997, 232, 351–358. [Google Scholar] [CrossRef] [PubMed]
  33. Kather, A.; Raftery, M.J.; Devi-Rao, G.; Lippmann, J.; Giese, T.; Sandri-Goldin, R.M.; Schönrich, G. Herpes simplex virus type 1 (HSV-1)-induced apoptosis in human dendritic cells as a result of downregulation of cellular FLICE-inhibitory protein and reduced expression of HSV-1 antiapoptotic latency-associated transcript sequences. J. Virol. 2010, 84, 1034–1046. [Google Scholar] [CrossRef] [PubMed]
  34. Lilley, C.E.; Carson, C.T.; Muotri, A.R.; Gage, F.H.; Weitzman, M.D. DNA repair proteins affect the lifecycle of herpes simplex virus 1. Proc. Natl. Acad. Sci. USA 2005, 102, 5844–5849. [Google Scholar] [CrossRef]
  35. Brown, S.H.; States, V.; Afghan, A.K.; Satyanarayana, G. Herpes simplex virus-infected squamous cell carcinoma: A case report. BMC Infect. Dis. 2022, 22, 25. [Google Scholar] [CrossRef] [PubMed]
  36. Hagglund, R.; Munger, J.; Poon, A.P.; Roizman, B. U(S)3 protein kinase of herpes simplex virus 1 blocks caspase 3 activation induced by the products of U(S)1.5 and U(L)13 genes and modulates expression of transduced U(S)1.5 open reading frame in a cell type-specific manner. J. Virol. 2002, 76, 743–754. [Google Scholar] [CrossRef] [PubMed]
  37. Wang, X.; Patenode, C.; Roizman, B. US3 protein kinase of HSV-1 cycles between the cytoplasm and nucleus and interacts with programmed cell death protein 4 (PDCD4) to block apoptosis. Proc. Natl. Acad. Sci. USA 2011, 108, 14632–14636. [Google Scholar] [CrossRef] [PubMed]
  38. Turunen, A.; Hukkanen, V.; Kulmala, J.; Syrjanen, S. HSV-1 Infection Modulates the Radioresponse of a HPV16-positive Head and Neck Cancer Cell Line. Anticancer Res. 2016, 36, 565–574. [Google Scholar]
  39. Giacobbe, D.R.; Di Bella, S.; Lovecchio, A.; Ball, L.; De Maria, A.; Vena, A.; Bruzzone, B.; Icardi, G.; Pelosi, P.; Luzzati, R.; et al. Herpes Simplex Virus 1 (HSV-1) Reactivation in Critically Ill COVID-19 Patients: A Brief Narrative Review. Infect. Dis. Ther. 2022, 11, 1779–1791. [Google Scholar] [CrossRef]
  40. Jalouli, J.; Jalouli, M.M.; Sapkota, D.; Ibrahim, S.O.; Larsson, P.A.; Sand, L. Human papilloma virus, herpes simplex virus and epstein barr virus in oral squamous cell carcinoma from eight different countries. Anticancer Res. 2012, 32, 571–580. [Google Scholar]
  41. Dabouian, A.; Tabibzadeh, A.; Salimi-Jeda, A.; Torkashvand, S.; Panahi, M.; Tameshkel, F.S.; Zamani, F.; Keyvani, H.; Niya, M.H.K. The Molecular Epidemiology of Herpes Simplex Virus Type 1 and 2 (HSV-1 and HSV-2) in Head and Neck Cancer (HNC). Int. J. Cancer Manag. 2020, 13, e105916. [Google Scholar] [CrossRef]
  42. Liljeqvist, J.Å.; Tunbäck, P.; Norberg, P. Asymptomatically shed recombinant herpes simplex virus type 1 strains detected in saliva. J. Gen. Virol. 2009, 90 Pt 3, 559–566. [Google Scholar] [CrossRef] [PubMed]
  43. Polz-Gruszka, D.; Stec, A.; Dworzański, J.; Polz-Dacewicz, M. EBV, HSV, CMV and HPV in laryngeal and oropharyngeal carcinoma in Polish patients. Anticancer Res. 2015, 35, 1657–1661. [Google Scholar]
  44. Bashir, R.A.; Elhag, W.I. Molecular Detection of Herpes Simplex Virus Types [1 and 2] in Orophar yngeal Squamous Cell Carcinoma (OSCC) in Khartoum Dental Education Hospital. J. Adv. Med. Med. Res. 2018, 26, 1–6. [Google Scholar] [CrossRef]
  45. Delavarian, Z.; Pakfetrat, A.; Falaki, F.; Pazouki, M.; Pazouki, N. The Role of Viruses in Oral Squamous Cell Carcinoma in Young Patients in Khorasan (Northeast of Iran). J. Appl. Sci. 2010, 10, 981–985. [Google Scholar] [CrossRef]
  46. Maden, C.; Beckmann, A.M.; Thomas, D.B.; McKnight, B.; Sherman, K.J.; Ashley, R.L.; Corey, L.; Daling, J.R. Human papillomaviruses, herpes simplex viruses, and the risk of oral cancer in men. Am. J. Epidemiol. 1992, 135, 1093–1102. [Google Scholar] [CrossRef]
  47. Mokhtari, M.; Beiraghdar, M. Evaluation of the prevalence of herpes simplex-1 infection in oral squamous cell carcinoma specimens in Alzahra and Kashani Hospitals with polymerase chain reaction method in 2012-2013. Adv. Biomed. Res. 2015, 4, 173. [Google Scholar]
  48. Osman, S.A.; Enan, K.A.; Mohamed, E.A. Molecular detection of herpes simplex virus (1, 2) in oral squamous cell carcinoma at Khartoum. Clin. Med. J. 2017, 2, 10–14. [Google Scholar]
  49. Devilleres-Mendoza, D.D.; Chang, J.V. Cytopathologic Herpes Simplex Virus Features In Laryngeal Squamous Cell Carcinoma. PhiliPPine J. Otolaryngol.-Head Neck Surg. 2016, 31, 61–64. [Google Scholar] [CrossRef]
  50. Shillitoe, E.J.; Greenspan, D.; Greenspan, J.S.; Silverman, S., Jr. Immunoglobulin class of antibody to herpes simplex virus in patients with oral cancer. Cancer 1983, 51, 65–71. [Google Scholar] [CrossRef] [PubMed]
  51. Meurman, J.H. Infectious and dietary risk factors of oral cancer. Oral Oncol. 2010, 46, 411–413. [Google Scholar] [CrossRef]
  52. Saravanan, M.; Kolade Omole, R.; Torimiro, N. Oncogenic virus in oral squamous cell carcinoma and the role of oncolytic HSV-1 viro-immunotherapy as an emerging treatment. Oral Oncol. 2022, 133, 106021. [Google Scholar] [CrossRef] [PubMed]
  53. Strojnik, T.; Duh, D.; Lah, T.T. Prevalence of Neurotropic Viruses in Malignant Glioma and Their Onco-Modulatory Potential. Vivo 2017, 31, 221–229. [Google Scholar] [CrossRef] [PubMed]
  54. Saddawi-Konefka, R.; Crawford, J.R. Chronic viral infection and primary central nervous system malignancy. J. Neuroimmune Pharmacol. 2010, 5, 387–403. [Google Scholar] [CrossRef]
  55. Kofman, A.; Marcinkiewicz, L.; Dupart, E.; Lyshchev, A.; Martynov, B.; Ryndin, A.; Kotelevskaya, E.; Brown, J.; Schiff, D.; Abounader, R. The roles of viruses in brain tumor initiation and oncomodulation. J. Neurooncol. 2011, 105, 451–466. [Google Scholar] [CrossRef]
  56. Pfeffer, S.; Sewer, A.; Lagos-Quintana, M.; Sheridan, R.; Sander, C.; Grässer, F.A.; van Dyk, L.F.; Ho, C.K.; Shuman, S.; Chien, M.; et al. Identification of microRNAs of the herpesvirus family. Nat. Methods 2005, 2, 269–276. [Google Scholar] [CrossRef]
  57. Vassallo, J.; Camargo, L.A.; Chagas, C.A.; Pinto, G.A.; Endo, L.H. Search for Herpesvirus 1 and 2 by in situ hybridization in tonsils and adenoids. Int. J. Pediatr. Otorhinolaryngol. 2005, 69, 345–349. [Google Scholar] [CrossRef]
  58. Sahin, F.; Gerceker, D.; Karasartova, D.; Ozsan, T.M. Detection of herpes simplex virus type 1 in addition to Epstein-Bar virus in tonsils using a new multiplex polymerase chain reaction assay. Diagn. Microbiol. Infect. Dis. 2007, 57, 47–51. [Google Scholar] [CrossRef]
  59. Sahiner, F.; Gümral, R.; Yildizoğlu, Ü.; Babayiğit, M.A.; Durmaz, A.; Yiğit, N.; Saraçli, M.A.; Kubar, A. Coexistence of Epstein-Barr virus and Parvovirus B19 in tonsillar tissue samples: Quantitative measurement by real-time PCR. Int. J. Pediatr. Otorhinolaryngol. 2014, 78, 1288–1293. [Google Scholar] [CrossRef]
  60. Lévy, P.; Kohler, M.; McNicholas, W.T.; Barbé, F.; McEvoy, R.D.; Somers, V.K.; Lavie, L.; Pépin, J.L. Obstructive sleep apnoea syndrome. Nat. Rev. Dis. Prim. 2015, 1, 15015. [Google Scholar] [CrossRef]
  61. Deegan, P.C.; McNicholas, W.T. Pathophysiology of obstructive sleep apnoea. Eur. Respir. J. 1995, 8, 1161–1178. [Google Scholar] [CrossRef] [PubMed]
  62. Patil, S.P.; Ayappa, I.A.; Caples, S.M.; Kimoff, R.J.; Patel, S.R.; Harrod, C.G. Treatment of Adult Obstructive Sleep Apnea With Positive Airway Pressure: An American Academy of Sleep Medicine Systematic Review, Meta-Analysis, and GRADE Assessment. J. Clin. Sleep Med. 2019, 15, 301–334. [Google Scholar] [CrossRef]
  63. Antonopoulos, C.N.; Sergentanis, T.N.; Daskalopoulou, S.S.; Petridou, E.T. Nasal continuous positive airway pressure (nCPAP) treatment for obstructive sleep apnea, road traffic accidents and driving simulator performance: A meta-analysis. Sleep Med. Rev. 2011, 15, 301–310. [Google Scholar] [CrossRef] [PubMed]
  64. van Veldhuisen, S.L.; van Boxel, M.F.; Wiezer, M.J.; van Veen, R.N.; de Castro, S.M.M.; Swank, D.J.; Demirkiran, A.; Boerma, E.G.; Greve, J.W.M.; van Dielen, F.M.H.; et al. Evaluation of CPAP adherence in bariatric patients diagnosed with obstructive sleep apnea: Outcomes of a multicenter cohort study. Sleep Breath 2022, 1–10. [Google Scholar] [CrossRef]
  65. Iannella, G.; Lechien, J.R.; Perrone, T.; Meccariello, G.; Cammaroto, G.; Cannavicci, A.; Burgio, L.; Maniaci, A.; Cocuzza, S.; Di Luca, M.; et al. Barbed reposition pharyngoplasty (BRP) in obstructive sleep apnea treatment: State of the art. Am. J. Otolaryngol. 2022, 43, 103197. [Google Scholar] [CrossRef]
  66. Verbraecken, J.; Dieltjens, M.; Op de Beeck, S.; Vroegop, A.; Braem, M.; Vanderveken, O.; Randerath, W. Non-CPAP therapy for obstructive sleep apnoea. Breathe 2022, 18, 220164. [Google Scholar] [CrossRef]
  67. Gambino, F.; Zammuto, M.M.; Virzì, A.; Conti, G.; Bonsignore, M.R. Treatment options in obstructive sleep apnea. Intern. Emerg. Med. 2022, 17, 971–978. [Google Scholar] [CrossRef] [PubMed]
  68. James, C.; Harfouche, M.; Welton, N.J.; Turner, K.M.; Abu-Raddad, L.J.; Gottlieb, S.L.; Looker, K.J. Herpes simplex virus: Global infection prevalence and incidence estimates, 2016. Bull World Health Organ. 2020, 98, 315–329. [Google Scholar] [CrossRef]
  69. Yousuf, W.; Ibrahim, H.; Harfouche, M.; Abu Hijleh, F.; Abu-Raddad, L. Herpes simplex virus type 1 in Europe: Systematic review, meta-analyses and meta-regressions. BMJ Glob. Health 2020, 5, e002388. [Google Scholar] [CrossRef]
  70. Dworzański, J.; Drop, B.; Kliszczewska, E.; Strycharz-Dudziak, M.; Polz-Dacewicz, M. Prevalence of Epstein-Barr virus, human papillomavirus, cytomegalovirus and herpes simplex virus type 1 in patients with diabetes mellitus type 2 in south-eastern Poland. PLoS ONE 2019, 14, e0222607. [Google Scholar] [CrossRef] [PubMed]
  71. Olsson, J.; Kok, E.; Adolfsson, R.; Lövheim, H.; Elgh, F. Herpes virus seroepidemiology in the adult Swedish population. Immun. Ageing 2017, 14, 10. [Google Scholar] [CrossRef]
  72. Malkin, J.E.; Morand, P.; Malvy, D.; Ly, T.D.; Chanzy, B.; de Labareyre, C.; El Hasnaoui, A.; Hercberg, S. Seroprevalence of HSV-1 and HSV-2 infection in the general French population. Sex. Transm. Infect. 2002, 78, 201–203. [Google Scholar] [CrossRef] [PubMed]
  73. Marchi, S.; Trombetta, C.M.; Gasparini, R.; Temperton, N.; Montomoli, E. Epidemiology of herpes simplex virus type 1 and 2 in Italy: A seroprevalence study from 2000 to 2014. J. Prev. Med. Hyg. 2017, 58, E27–E33. [Google Scholar] [PubMed]
  74. McQuillan, G.; Kruszon-Moran, D.; Flagg, E.W.; Paulose-Ram, R. Prevalence of Herpes Simplex Virus Type 1 and Type 2 in Persons Aged 14-49: United States, 2015-2016. NCHS Data Brief. 2018, 1–8. Available online: https://www.cdc.gov/nchs/products/databriefs/db304.htm (accessed on 25 April 2023).
  75. Sukik, L.; Alyafei, M.; Harfouche, M.; Abu-Raddad, L.J. Herpes simplex virus type 1 epidemiology in Latin America and the Caribbean: Systematic review and meta-analytics. PLoS ONE 2019, 14, e0215487. [Google Scholar] [CrossRef] [PubMed]
  76. Doi, Y.; Ninomiya, T.; Hata, J.; Yonemoto, K.; Tanizaki, Y.; Arima, H.; Liu, Y.; Rahman, M.; Iida, M.; Kiyohara, Y. Seroprevalence of herpes simplex virus 1 and 2 in a population-based cohort in Japan. J. Epidemiol. 2009, 19, 56–62. [Google Scholar] [CrossRef] [PubMed]
  77. Malary, M.; Abedi, G.; Hamzehgardeshi, Z.; Afshari, M.; Moosazadeh, M. The prevalence of herpes simplex virus type 1 and 2 infection in Iran: A meta-analysis. Int. J. Reprod. Biomed. 2016, 14, 615–624. [Google Scholar] [CrossRef]
  78. Harfouche, M.; Chemaitelly, H.; Abu-Raddad, L.J. Herpes simplex virus type 1 epidemiology in Africa: Systematic review, meta-analyses, and meta-regressions. J. Infect. 2019, 79, 289–299. [Google Scholar] [CrossRef]
  79. Katz, I.; De Luca, F.; Dzudzor, B.; Sarpong, B.K.; Osei-Appiah, B.; Azoulay, D.; Katz, D.; Dey, D.; Gilburd, B.; Amital, H.; et al. Seroprevalences of autoantibodies and anti- infectious antibodies among Ghana&#39;s healthy population. Sci. Rep. 2020, 10, 2814. [Google Scholar]
  80. Palacios-Pedrero, M.Á.; Osterhaus, A.D.M.E.; Becker, T.; Elbahesh, H.; Rimmelzwaan, G.F.; Saletti, G. Aging and Options to Halt Declining Immunity to Virus Infections. Front. Immunol. 2021, 12, 681449. [Google Scholar] [CrossRef]
  81. Wald, A.; Ashley-Morrow, R. Serological testing for herpes simplex virus (HSV)-1 and HSV-2 infection. Clin. Infect. Dis. 2002, 35 (Suppl. 2), S173–S182. [Google Scholar] [CrossRef]
  82. Miller, C.S.; Danaher, R.J. Asymptomatic shedding of herpes simplex virus (HSV) in the oral cavity. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. 2008, 105, 43–50. [Google Scholar] [CrossRef]
  83. Koelle, D.M.; Magaret, A.; Warren, T.; Schellenberg, G.D.; Wald, A. APOE genotype is associated with oral herpetic lesions but not genital or oral herpes simplex virus shedding. Sex. Transm. Infect. 2010, 86, 202–206. [Google Scholar] [CrossRef] [PubMed]
  84. Mark, K.E.; Wald, A.; Magaret, A.S.; Selke, S.; Olin, L.; Huang, M.L.; Corey, L. Rapidly cleared episodes of herpes simplex virus reactivation in immunocompetent adults. J. Infect. Dis. 2008, 198, 1141–1149. [Google Scholar] [CrossRef]
  85. Ramchandani, M.S.; Jing, L.; Russell, R.M.; Tran, T.; Laing, K.J.; Magaret, A.S.; Selke, S.; Cheng, A.; Huang, M.L.; Xie, H.; et al. Viral Genetics Modulate Orolabial Herpes Simplex Virus Type 1 Shedding in Humans. J. Infect. Dis. 2019, 219, 1058–1066. [Google Scholar] [CrossRef]
  86. Yap, T.; Khor, S.; Kim, J.S.; Kim, J.; Kim, S.Y.; Kern, J.S.; Martyres, R.; Varigos, G.; Chan, H.T.; McCullough, M.J.; et al. Intraoral human herpes viruses detectable by PCR in majority of patients. Oral Dis. 2021, 27, 378–387. [Google Scholar] [CrossRef] [PubMed]
  87. Margolis, T.P.; Imai, Y.; Yang, L.; Vallas, V.; Krause, P.R. Herpes simplex virus type 2 (HSV-2) establishes latent infection in a different population of ganglionic neurons than HSV-1: Role of latency-associated transcripts. J. Virol. 2007, 81, 1872–1878. [Google Scholar] [CrossRef]
  88. Kizilay, A.; Saydam, L.; Aydin, A.; Kalcioglu, M.T.; Ozturan, O.; Aydin, N.E. Histopathologic examination for Helicobacter pylori as a possible etiopathogenic factor in laryngeal carcinoma. Chemotherapy 2006, 52, 80–82. [Google Scholar] [CrossRef]
  89. Fernando, N.; Jayakumar, G.; Perera, N.; Amarasingha, I.; Meedin, F.; Holton, J. Presence of Helicobacter pylori in betel chewers and non betel chewers with and without oral cancers. BMC Oral Health 2009, 9, 23. [Google Scholar] [CrossRef] [PubMed]
  90. Gong, H.; Shi, Y.; Zhou, L.; Tao, L.; Shi, Y.; Cao, W.; Cheng, L. Helicobacter pylori infection of the larynx may be an emerging risk factor for laryngeal squamous cell carcinoma. Clin. Transl. Oncol. 2012, 14, 905–910. [Google Scholar] [CrossRef]
  91. Ozdek, A.; Cirak, M.Y.; Samim, E.; Bayiz, U.; Safak, M.A.; Turet, S. A possible role of Helicobacter pylori in chronic rhinosinusitis: A preliminary report. Laryngoscope 2003, 113, 679–682. [Google Scholar]
  92. Morinaka, S.; Tominaga, M.; Nakamura, H. Detection of Helicobacter pylori in the middle ear fluid of patients with otitis media with effusion. Otolaryngol.-Head Neck Surg. 2005, 133, 791–794. [Google Scholar] [CrossRef]
  93. Burduk, P.K.; Kaczmarek, A.; Budzynska, A.; Kazmierczak, W.; Gospodarek, E. Detection of Helicobacter pylori and cagA gene in nasal polyps and benign laryngeal diseases. Arch. Med. Res. 2011, 42, 686–689. [Google Scholar] [CrossRef]
  94. Cekin, E.; Ozyurt, M.; Erkul, E.; Ergunay, K.; Cincik, H.; Kapucu, B.; Gungor, A. The association between Helicobacter pylori and laryngopharyngeal reflux in laryngeal pathologies. Ear Nose Throat J. 2012, 91, E6–E9. [Google Scholar] [CrossRef] [PubMed]
  95. Jelavic, B.; Petricevic, J.; Marijanović, I.; Bevanda, M. Helicobacter pylori in Otorhinolaryngology: Cause or Bystander. Eurasian J. Med. 2019, 51, 196–202. [Google Scholar]
  96. Meng, X.; Wang, Q.; He, C.; Chen, M.; Liu, J.; Liu, W.; Yuan, Y. An inverse association of Helicobacter pylori infection with oral squamous cell carcinoma. J. Oral Pathol. Med. 2016, 45, 17–22. [Google Scholar] [CrossRef]
  97. Zhou, J.; Zhang, D.; Yang, Y.; Zhou, L.; Tao, L. Association between helicobacter pylori infection and carcinoma of the larynx or pharynx. Head Neck. 2016, 38 (Suppl. 1), E2291–E2296. [Google Scholar] [CrossRef]
  98. Lukeš, P.; Pavlík, E.; Potuznikova, B.; Nartova, E.; Foltynova, E.; Plzak, J.; Katra, R.; Sterzl, I.; Bartunkova, J.; Betka, J.; et al. Detection of Helicobacter pylori in oropharyngeal lymphatic tissue with real-time PCR and assessment of its carcinogenic potential. Eur. Arch. Otorhinolaryngol. 2014, 271, 399–405. [Google Scholar] [CrossRef] [PubMed]
  99. Meng, W.P.; Wang, Z.Q.; Deng, J.Q.; Liu, Y.; Deng, M.M.; Lü, M.H. The Role of H. pylori CagA in Regulating Hormones of Functional Dyspepsia Patients. Gastroenterol. Res. Pract. 2016, 2016, 7150959. [Google Scholar] [CrossRef]
  100. Yilmaz, T.; Ceylan, M.; Akyön, Y.; Özçakýr, O.; Gürsel, B. Helicobacter pylori: A possible association with otitis media with effusion. Otolaryngol. Head Neck Surg. 2006, 134, 772–777. [Google Scholar] [CrossRef] [PubMed]
  101. Mohtasham, N.; Saghravanian, N.; Zare, R.; Saghafi, S.; Ghazi, N.; Mohajertehran, F.; Shahabinejad, M. Tumor tissue Helicobacter pylori and human papillomavirus infection in head and neck squamous cell carcinoma patients and association with clinicopathological indices: A cross-sectional medical survey. Dent. Res. J. 2022, 19, 8. [Google Scholar]
  102. Akbayir, N.; Başak, T.; Seven, H.; Sungun, A.; Erdem, L. Investigation of Helicobacter pylori colonization in laryngeal neoplasia. Eur. Arch. Oto-Rhino-Laryngol. 2005, 262, 170–172. [Google Scholar] [CrossRef] [PubMed]
  103. Morand, G.B.; Fellmann, J.; Laske, R.D.; Weisert, J.U.; Soltermann, A.; Zbinden, R.; Probst, R.; Huber, G.F. Detection of Helicobacter pylori in patients with head and neck cancer: Results from a prospective comparative study combining serology, polymerase chain reaction, and rapid urease test. Head Neck 2016, 38, 769–774. [Google Scholar] [CrossRef]
  104. Masoud, N.; Manouchehr, K.; Najmeh, D.; Monireh, H. Lack of association between Helicobacter pylori and laryngeal carcinoma. Asian Pac. J. Cancer Prev. 2008, 9, 81–82. [Google Scholar] [PubMed]
  105. Pandey, S.; Jha, H.C.; Shukla, S.K.; Shirley, M.K.; Robertson, E.S. Epigenetic Regulation of Tumor Suppressors by Helicobacter pylori Enhances EBV-Induced Proliferation of Gastric Epithelial Cells. mBio 2018, 9, e00649-18. [Google Scholar] [CrossRef] [PubMed]
  106. Burduk, P.K. Rola infekcji helicobacter pylori w patogenezie raka krtani [The role of helicobacter pylori infection in carcinoma of the larynx]. Otolaryngol. Pol. 2006, 60, 521–523. (In Polish) [Google Scholar] [PubMed]
  107. Burduk, P.K. Association between infection of virulence cagA gene Helicobacter pylori and laryngeal squamous cell carcinoma. Med. Sci. Monit. 2013, 19, 584–591. [Google Scholar] [CrossRef] [PubMed]
  108. Aygenc, E.; Selcuk, A.; Celikkanat, S.; Ozbek, C.; Ozdem, C. The role of Helicobacter pylori infection in the cause of squamous cell carcinoma of the larynx. Otolaryngol. Head Neck Surg. 2001, 125, 520–521. [Google Scholar] [CrossRef]
  109. Titiz, A.; Ozcakir, O.; Ceyhan, S.; Yilmaz, Y.F.; Unal, A.; Akyon, Y. The presence of Helicobacter pylori in the larynx pathologies. Auris Nasus Larynx 2008, 35, 534–538. [Google Scholar] [CrossRef]
  110. Shi, Y.; Gong, H.; Zhou, L.; Tao, L.; Shi, Y.; Cao, W.; Cheng, L. Association between Helicobacter pylori infection and laryngeal squamous cell carcinoma in a Chinese male population. ORL J. Otorhinolaryngol. Relat. Spec. 2011, 73, 295–300. [Google Scholar] [CrossRef]
  111. Astl, J.; Holy, R.; Maute, E.; Rotnágl, J.; Kalfeřt, D.; Drnková, B.; Younus, T.; Pavlík, E. Genome of Helicobacter pylori and Serotype of HPV Detected in Oropharyngeal and Laryngeal Cancer and Chronic Inflammation Patients. Int. J. Environ. Res. Public Health 2021, 18, 9545. [Google Scholar] [CrossRef]
  112. Pajić Matić, I.; Matić, I.; Maslovara, S.; Veselski, K.; Stojadinović, T.; Vučković, I. Helicobacter pylori gastric infection in patients with laryngeal cancer and chronic laryngitis. Eur. Arch. Oto-Rhino-Laryngol. 2021, 278, 135–139. [Google Scholar] [CrossRef]
  113. Rezaii, J.; Tavakoli, H.; Esfandiari, K.; Ashegh, H.; Hasibi, M.; Ghanei, G.; Khosh-Batn, M.; Rashidi, A. Association between Helicobacter pylori infection and laryngohypopharyngeal carcinoma: A case-control study and review of the literature. Head Neck 2008, 30, 1624–1627. [Google Scholar] [CrossRef]
  114. Kariya, S.; Okano, M.; Nishizaki, K. An association between Helicobacter pylori and upper respiratory tract disease: Fact or fiction? World J. Gastroenterol. 2014, 20, 1470–1484. [Google Scholar] [CrossRef] [PubMed]
  115. Mao, X.; Jakubovics, N.S.; Bächle, M.; Buchalla, W.; Hiller, K.A.; Maisch, T.; Hellwig, E.; Kirschneck, C.; Gessner, A.; Al-Ahmad, A.; et al. Colonization of Helicobacter pylori in the oral cavity—An endless controversy? Crit. Rev. Microbiol. 2021, 47, 612–629. [Google Scholar] [CrossRef] [PubMed]
  116. Aslan, S.; Yilmaz, I.; Bal, N.; Sener, M.; Butros, R.; Demirhan, B.; Ozluoglu, L.N. Investigation of Helicobacter pylori in tonsillary tissue with Pronto Dry test and pathologic examination. Auris Nasus Larynx 2007, 34, 339–342. [Google Scholar] [CrossRef] [PubMed]
  117. Lin, H.C.; Wu, P.Y.; Friedman, M.; Chang, H.W.; Wilson, M. Difference of Helicobacter pylori colonization in recurrent inflammatory and simple hyperplastic tonsil tissues. Arch. Otolaryngol. Head Neck Surg. 2010, 136, 468–470. [Google Scholar] [CrossRef]
  118. Güçlü, O.; Akçalı, A.; Sahin, E.M.; Tekin, K.; Barutçu, O.; Otkun, M.T.; Dereköy, F.S. Relationship between Helicobacter pylori Adenotonsillar Colonization and Frequency of Adenotonsillitis in Children. Balk. Med. J. 2013, 30, 301–304. [Google Scholar] [CrossRef]
  119. Nártová, E.; Kraus, J.; Pavlík, E.; Lukeš, P.; Katra, R.; Plzák, J.; Kolářová, L.; Sterzl, I.; Betka, J.; Astl, J. Presence of different genotypes of Helicobacter pylori in patients with chronic tonsillitis and sleep apnoea syndrome. Eur. Arch. Otorhinolaryngol. 2014, 271, 607–613. [Google Scholar] [CrossRef]
  120. Siupsinskiene, N.; Katutiene, I.; Jonikiene, V.; Janciauskas, D.; Vaitkus, S. Helicobacter pylori in the tonsillar tissue: A possible association with chronic tonsillitis and laryngopharyngeal reflux. J. Laryngol. Otol. 2017, 131, 549–556. [Google Scholar] [CrossRef]
  121. Wu, X.; Wang, W.; Fang, L.; Shi, L.; Rao, X. Is Helicobacter pylori colonization associated with chronic tonsillitis? - A meta-analysis and systematic review. Am. J. Otolaryngol. 2022, 43, 103515. [Google Scholar] [CrossRef]
  122. Burne, R.A.; Chen, Y.Y. Bacterial ureases in infectious diseases. Microbes. Infect. 2000, 2, 533–542. [Google Scholar] [CrossRef]
  123. Celiński, K.; Kurzeja-Mirosław, A.; Słomka, M.; Cichoz-Lach, H.; Madro, A.; Kasztelan-Szczerbińska, B. The effects of environmental factors on the prevalence of Helicobacter pylori infection in inhabitants of Lublin Province. Ann. Agric. Env. Med. 2006, 13, 185–191. [Google Scholar]
  124. Szczepanik, A.B.; Zaleska, M.; Wiszniewski, A.; Wislawski, S.; Misiak, A.; Maryniak, R.; Windyga, J. Helicobacter pylori infection in patients with haemophilia in Poland: Prevalence and risk of upper gastrointestinal bleeding. Haemophilia. 2005, 11, 376–379. [Google Scholar] [CrossRef]
  125. Bureš, J.; Kopáčová, M.; Koupil, I.; Seifert, B.; Skodová Fendrichová, M.; Spirková, J.; Voříšek, V.; Rejchrt, S.; Douda, T.; Král, N.; et al. Significant decrease in prevalence of Helicobacter pylori in the Czech Republic. World J. Gastroenterol. 2012, 18, 4412–4418. [Google Scholar] [CrossRef]
  126. Bálint, L.; Tiszai, A.; Kozák, G.; Dóczi, I.; Szekeres, V.; Inczefi, O.; Ollé, G.; Helle, K.; Róka, R.; Rosztóczy, A. Epidemiologic characteristics of Helicobacter pylori infection in southeast Hungary. World J. Gastroenterol. 2019, 25, 6365–6372. [Google Scholar] [CrossRef] [PubMed]
  127. van Blankenstein, M.; van Vuuren, A.J.; Looman, C.W.; Ouwendijk, M.; Kuipers, E.J. The prevalence of Helicobacter pylori infection in the Netherlands. Scand. J. Gastroenterol. 2013, 48, 794–800. [Google Scholar] [CrossRef]
  128. Lorenzo, I.; Fernández-de-Larrea, N.; Michel, A.; Romero, B.; Lope, V.; Bessa, X.; Moreno, V.; Martín, V.; Amiano, P.; Castilla, J.; et al. Helicobacter pylori seroprevalence in Spain: Influence of adult and childhood sociodemographic factors. Eur. J. Cancer Prev. 2019, 28, 294–303. [Google Scholar] [CrossRef]
  129. Roberts, S.E.; Morrison-Rees, S.; Samuel, D.G.; Thorne, K.; Akbari, A.; Williams, J.G. Review article: The prevalence of Helicobacter pylori and the incidence of gastric cancer across Europe. Aliment. Pharmacol. Ther. 2016, 43, 334–345. [Google Scholar] [CrossRef] [PubMed]
  130. Zhou, J.; Wang, X.; Liu, K.; Chen, K. Association between Helicobacter pylori infection and the risk of type 2 diabetes mellitus based on a middle-aged and elderly Chinese population. Endocr. J. 2022, 69, 839–846. [Google Scholar] [CrossRef]
  131. Ito, M.; Sugiyama, A.; Mino, M.; Kodama, M.; Nagaoki, Y.; Abe, K.; Imada, H.; Ouoba, S.E.B.; Ko, K.; Akita, T.; et al. Prevalence of Helicobacter pylori infection in the general population evaluated by a resident-register-based epidemiological study. J. Gastroenterol. 2022, 57, 540–546. [Google Scholar] [CrossRef] [PubMed]
  132. Mežmale, L.; Polaka, I.; Rudzite, D.; Vangravs, R.; Kikuste, I.; Parshutin, S.; Daugule, I.; Tazhedinov, A.; Belikhina, T.; Igissinov, N.; et al. Prevalence and Potential Risk Factors of Helicobacter pylori Infection among Asymptomatic Individuals in Kazakhstan. Asian Pac. J. Cancer Prev. 2021, 22, 597–602. [Google Scholar] [CrossRef]
  133. Zaterka, S.; Eisig, J.N.; Chinzon, D.; Rothstein, W. Factors related to Helicobacter pylori prevalence in an adult population in Brazil. Helicobacter 2007, 12, 82–88. [Google Scholar] [CrossRef] [PubMed]
  134. Willems, P.; de Repentigny, J.; Hassan, G.M.; Sidani, S.; Soucy, G.; Bouin, M. The Prevalence of Helicobacter pylori Infection in a Quaternary Hospital in Canada. J. Clin. Med. Res. 2020, 12, 687–692. [Google Scholar] [CrossRef] [PubMed]
  135. Kadota, T.; Hamada, M.; Nomura, R.; Ogaya, Y.; Okawa, R.; Uzawa, N.; Nakano, K. Distribution of Helicobacter pylori and Periodontopathic Bacterial Species in the Oral Cavity. Biomedicines 2020, 8, 161. [Google Scholar] [CrossRef]
  136. Šeligová, B.; Lukáč, Ľ.; Bábelová, M.; Vávrová, S.; Sulo, P. Diagnostic reliability of nested PCR depends on the primer design and threshold abundance of Helicobacter pylori in biopsy, stool, and saliva samples. Helicobacter 2020, 25, e12680. [Google Scholar] [CrossRef] [PubMed]
Diagnostics 13 01798 g001 550
Figure 1. Absolute and percent prevalence of HSV-1 (A) or H. pylori (B) in patients with HNSCC, chronic tonsillitis, and controls.
Figure 1. Absolute and percent prevalence of HSV-1 (A) or H. pylori (B) in patients with HNSCC, chronic tonsillitis, and controls.
Diagnostics 13 01798 g001
Table
Table 1. Distribution of sociodemographic characteristics in patients with HNSCC, chronic tonsillitis, and controls.
Table 1. Distribution of sociodemographic characteristics in patients with HNSCC, chronic tonsillitis, and controls.
AllHNSCCChronic TonsillitisControl
MedianRangeMedianRangeMedianRangeMedianRange
Age4129–57.56052–653324–413324–49.25
N%N%N%N%
Age ≥ 4015351.868493.332627.964338.39
Age < 4014248.1466.676772.046961.61
Female14047.462628.895154.846356.25
Male15552.546471.114245.164943.75
Smoking10936.956572.221415.053127.68
Not smoking18663.052527.787984.958172.32
Drinking18261.696167.782931.189282.14
Regular drinking227.461112.2233.2387.14
Occasional drinking16054.245055.562627.968475.00
Not drinking 11338.312932.226468.822017.86
Smoking and drinking8528.815055.5688.602724.11
Drinking; not smoking9632.541112.222021.516558.04
Smoking; not drinking268.811516.6777.5343.57
Not smoking; not drinking8829.831415.565862.371614.29
Table
Table 2. Clinical characteristics of patients with HNSCC.
Table 2. Clinical characteristics of patients with HNSCC.
N(%)
Clinical T-classification 90(100.00)
T11011.1
T22224.4
T32831.1
T43033.3
T1 + T23235.6
T3 + T45864.4
Lymph node status 90(100.00)
N04347.8
N12224.4
N22224.4
N333.3
N1 + N24448.8
Histological grade 90(100.00)
G11516.7
G25662.2
G31921.1
G1 + G27178.9
Stage 90(100.00)
I77.78
II1213.33
III2123.33
IV5055.56
Table
Table 3. Statistical significance of the ratio between the groups with HSV-1 or H. pylori occurrence.
Table 3. Statistical significance of the ratio between the groups with HSV-1 or H. pylori occurrence.
HSV-1H. pylori
Control vs. HNSCC0.2830.035
Control vs. Chronic tonsillitis0.3760.353
Chronic tonsillitis vs. HNSCC0.8410.099
Bold and color indicate statistical significances with p < 0.05.
Table
Table 4. Sociodemographic characteristics (age, gender, drinking and smoking status) and their association with HSV-1 and H. pylori in patients with HNSCC, chronic tonsillitis, and controls.
Table 4. Sociodemographic characteristics (age, gender, drinking and smoking status) and their association with HSV-1 and H. pylori in patients with HNSCC, chronic tonsillitis, and controls.
Study GroupVariableVariantHSV-1pH. pylorip
NegativePositiveNegativePositive
HNSCCAge≥4077718401
<406060
GenderFemale2330.4072601
Male604640
DrinkingYes5560.4226101
No281290
SmokingYes5960.6686501
No241250
Chronic tonsillitisAge≥4024212420.188
<40616661
GenderFemale47414921
Male384391
DrinkingYes27212720.228
No586631
SmokingYes1130.0971401
No745763
ControlAge≥403490.0424031
<40645654
GenderFemale5760.3896120.237
Male418445
DrinkingYes82100.2728661
No164191
SmokingYes2650.5272921
No729765
Bold and color indicate statistical significances with p < 0.05.
Table
Table 5. The prevalence of HSV-1 and H. pylori in the HNSCC group according to T classification and stage.
Table 5. The prevalence of HSV-1 and H. pylori in the HNSCC group according to T classification and stage.
Study GroupVariableVariantHSV-1pH. pylorip
NegativePositiveNegativePositive
HNSCCT1Yes10011001
No737800
T2Yes2200.1882201
No617680
T3Yes2710.4282801
No566620
T4Yes2460.0053001
No591600
T1 + T2Yes3200.0483201
No517580
T3 + T4Yes5170.0485801
No510320
Stage IYes701701
No767830
Stage IIYes1200.5881201
No717780
Stage IIIYes2100.1939001
No627690
Stage IVYes5070.0445001
No330400
Bold and color indicate statistical significances with p < 0.05.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Strzelczyk, J.K.; Świętek, A.; Hudy, D.; Gołąbek, K.; Gaździcka, J.; Miśkiewicz-Orczyk, K.; Ścierski, W.; Strzelczyk, J.; Misiołek, M. Low Prevalence of HSV-1 and Helicobacter pylori in HNSCC and Chronic Tonsillitis Patients Compared to Healthy Individuals. Diagnostics 2023, 13, 1798. https://doi.org/10.3390/diagnostics13101798

AMA Style

Strzelczyk JK, Świętek A, Hudy D, Gołąbek K, Gaździcka J, Miśkiewicz-Orczyk K, Ścierski W, Strzelczyk J, Misiołek M. Low Prevalence of HSV-1 and Helicobacter pylori in HNSCC and Chronic Tonsillitis Patients Compared to Healthy Individuals. Diagnostics. 2023; 13(10):1798. https://doi.org/10.3390/diagnostics13101798

Chicago/Turabian Style

Strzelczyk, Joanna Katarzyna, Agata Świętek, Dorota Hudy, Karolina Gołąbek, Jadwiga Gaździcka, Katarzyna Miśkiewicz-Orczyk, Wojciech Ścierski, Janusz Strzelczyk, and Maciej Misiołek. 2023. "Low Prevalence of HSV-1 and Helicobacter pylori in HNSCC and Chronic Tonsillitis Patients Compared to Healthy Individuals" Diagnostics 13, no. 10: 1798. https://doi.org/10.3390/diagnostics13101798

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop